Pharmacogenetic Insights: A Conversation With John J. Miller, MD

Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Psychiatric Times' very own editor in chief, John J. Miller, MD, to discuss the current state and future directions of pharmacogenetic testing. "Pharmacogenetics is almost like a Rorschach test in the eyes of many practitioners and patients. It is thought to be a projective that you sort of identify in various ways. It is going to tell me things about myself. It is going to make predictions. It is going to help me guide treatment. It is going to override clinical factors, patient specific features that influence outcome, and really get to the heart of things," said Goldberg. Miller shared his initial reactions to the introduction of this testing: "When pharmacogenetic testing first became available about 12 to 14 years ago, I was excited. And then, as I learned more about it, read the literature, and became aware of the institutions that exist to vet genes and whether or not they are clinically actionable, I became very frustrated by how overly adoptive pharmacogenomics has become when really the evidence base is not there. In fact, as we have learned more, it has become less evidence based in terms of clinical applications." ---------- 🔗 Read more: https://www.psychiatrictimes.com 📩 Subscribe for more: @PsychTimes 🌐 Visit us: https://www.psychiatrictimes.com ---------- Psychiatric Times is the No. 1 psychiatric publication in the US. Visit us at psychiatrictimes.com for the latest clinical news, expert perspectives, and CME opportunities. #psychiatry #psychiatrictimes #pharmacogenomics #psychopharmacology